OTLK (STOCKS)
Outlook Therapeutics, Inc. Common Stock
$0.765100
-0.123700 (-13.92%)
Prev close: $0.888800
Company Information
- Exchange
- XNAS
- Sector
- Health Technology
- Industry
- Pharmaceuticals: Major
- CEO
- Robert Charles Jahr
- Asset Type
- stocks
- Website
- Visit
Fundamentals
- Market Cap
- $143.07M
- Employees
- 23
- P/E (TTM)
- -0.81
- P/B (TTM)
- -3.21
- Dividend Yield
- —
Technical Indicators
- SMA 10
- —
- SMA 20
- —
- SMA 50
- —
- EMA 9
- —
- EMA 21
- —
- RSI
- —
- MACD State
- —
Analyst Recommendations
2
Strong Buy
5
Buy
3
Hold
0
Sell
Recent News
No recent news found for this ticker.
Earnings Surprises
| Period | Actual | Estimate | Surprise | Surprise % |
|---|---|---|---|---|
|
Sep 2026 (Q3)
|
$-0.09 | $-0.10 | +0.0052 | +5.46% |
|
Mar 2026 (Q2)
|
$-0.16 | $-0.12 | -0.0376 | -30.72% |
|
Dec 2025 (Q1)
|
$-0.22 | $-0.18 | -0.0432 | -24.43% |
|
Sep 2025 (Q4)
|
$-0.19 | $-0.26 | +0.0684 | +26.47% |
Financial Statements
| Revenues | $176.08K |
| Benefits Costs and Expenses | $62.69M |
| Cost Of Revenue | $1.54M |
| Costs And Expenses | $53.11M |
| Gross Profit | -$1.20M |
| Operating Expenses | $59.37M |
| Selling, General, and Administrative Expenses | $38.12M |
| Depreciation and Amortization | $119.64K |
| Research and Development | $21.25M |
| Operating Income/Loss | -$60.57M |
| Income/Loss Before Equity Method Investments | -$62.36M |
| Income/Loss From Continuing Operations After Tax | -$60.96M |
| Income/Loss From Continuing Operations Before Tax | -$62.51M |
| Income/Loss From Equity Method Investments | -$155.06K |
| Interest Income/Expense After Provision For Losses | -$313.50K |
| Interest Income/Expense Operating, Net | -$313.50K |
| Net Income/Loss | -$60.96M |
| Net Income/Loss Attributable To Noncontrolling Interest | $0.00 |
| Net Income/Loss Attributable To Parent | -$60.96M |
| Net Income/Loss Available To Common Stockholders, Basic | -$60.96M |
| Participating Securities, Distributed And Undistributed Earnings/Loss, Basic | $0.00 |
| Preferred Stock Dividends And Other Adjustments | $0.00 |
| Provision For Loan, Lease, And Other Losses | $0.00 |
| Basic Earnings Per Share | -$1.17 |
| Diluted Earnings Per Share | -$1.17 |
| Basic Average Shares | 183,129,649 |
| Diluted Average Shares | 183,129,649 |
| Assets | $21.89M |
| Current Assets | $20.90M |
| Inventory | $3.34M |
| Other Current Assets | $17.56M |
| Noncurrent Assets | $987.70K |
| Liabilities | $50.89M |
| Current Liabilities | $38.88M |
| Accounts Payable | $13.64M |
| Wages | $718.61K |
| Other Current Liabilities | $24.53M |
| Noncurrent Liabilities | $12.00M |
| Equity | -$28.99M |
| Equity Attributable To Noncontrolling Interest | $0.00 |
| Equity Attributable To Parent | -$28.99M |
| Liabilities And Equity | $21.89M |
| Net Cash Flow From Operating Activities | -$47.05M |
| Net Cash Flow From Operating Activities, Continuing | -$47.05M |
| Net Cash Flow From Investing Activities | -$191.91K |
| Net Cash Flow From Investing Activities, Continuing | -$191.91K |
| Net Cash Flow From Financing Activities | $47.24M |
| Net Cash Flow From Financing Activities, Continuing | $47.24M |
| Net Cash Flow | $0.00 |
| Net Cash Flow, Continuing | $0.00 |
| Comprehensive Income/Loss | -$60.96M |
| Comprehensive Income/Loss Attributable To Noncontrolling Interest | $0.00 |
| Comprehensive Income/Loss Attributable To Parent | -$60.96M |
| Other Comprehensive Income/Loss | $0.00 |